The new oral pill enlicitide cuts bad cholesterol risk by 60% in a new landmark trial. Here are the mechanisms behind it and ...

Enlicitide cholesterol pill shows up to 60 per cent reduction in LDL levels in trials. Here's how this new oral drug works, ...

Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder that leads to high levels of LDL ...

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered “bad” LDL cholesterol by more than half in a global study ...

A powerful new treatment has emerged in efforts to reduce high cholesterol levels and the associated risk of heart health problems. In a new trial, the drug enlicitide decanoate was found to lower ...

March 30 (Reuters) - Drugmaker Merck said on Monday its oral drug met the main goal of meaningfully reducing bad cholesterol ...

An experimental once-daily pill called enlicitide cut LDL cholesterol by 57% in a large Phase 3 clinical trial, a result researchers say could expand options for patients who struggle with existing ...

Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to deliver antibody-like efficacy and help address critical unmet needs for patients with HeFH to help combat the ...

A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A recent study, published in JAMA on November 9, investigates a drug called enlicitide. The ...

A new daily pill could reduce bad cholesterol levels by 60%, according to a new study. Enlicitide, which was developed by Merck, lowered "bad" LDL cholesterol by more than half in a global study ...